TABLE I. Baseline characteristics of genotype 1 chronic hepatitis C patients treated with PEG-IFN/RBV and rate of sustained virological response .
| Variable | All (n = 263) |
Non-SVR (n = 149) |
SVR (n = 114) |
p | |
|---|---|---|---|---|---|
| Age (years) (mean ± SD) | 50.4 ± 10.7 | 50.8 ± 10.1 | 48.9 ± 11.5 | 0.435a | |
| Sex (male) [n (%)] | 152 (58.6) | 92 (61.7) | 62 (54.4) | 0.257b | |
| ALT level (IU/L) (mean ± SD) | 96.3 ± 71.9 | 97.2 ± 70.8 | 95.2 ± 73.5 | 0.827c | |
| Viral load (IU/mL) [n (%)] | 0.001b | ||||
| < 600.000 | 56 (21.8) | 20 (13.8) | 36 (32.1) | - | |
| ≥ 600.000 | 201 (78.2) | 125 (86.2) | 76 (67.9) | - | |
| Metavir fibrosis stage [n (%)] | |||||
| F0-F2 | 146 (60.1) | 80 (58) | 66 (62.9) | 0.509 (F0-F2 vs. F3-F4)b | |
| F3-F4 | 97 (39.9 | 58 (42) | 39 (37.1) | - | |
| Cirrhosis | 41 (16.9) | 28 (20.3) | 13 (12.4) | 0.121 (cirrhosis vs. others)b | |
a: ANOVA; b: Student's t test; ALT: alanine aminotransferase; F0-F2 and F3-F4: Metavir score (mild/moderate and severe and cirrhosis, respectively); PEG-INF/RBV: pegylated interferon plus ribavirin (PEG-IFN/RBV); SD: standard deviation; SVR: sustained virological response.